Berenberg Bank Reiterates €75.00 Price Target for Gerresheimer (GXI)

Berenberg Bank set a €75.00 ($89.29) target price on Gerresheimer (ETR:GXI) in a research report released on Friday morning. The firm currently has a buy rating on the stock.

Several other analysts also recently weighed in on GXI. J P Morgan Chase & Co set a €99.40 ($118.33) price objective on Gerresheimer and gave the company a buy rating in a research report on Thursday, August 31st. Deutsche Bank set a €62.00 ($73.81) price objective on Gerresheimer and gave the company a neutral rating in a research report on Tuesday, September 5th. Independent Research set a €68.00 ($80.95) price objective on Gerresheimer and gave the company a neutral rating in a research report on Tuesday, September 5th. Hauck & Aufhaeuser set a €63.50 ($75.60) price objective on Gerresheimer and gave the company a neutral rating in a research report on Thursday, September 21st. Finally, set a €65.00 ($77.38) price objective on Gerresheimer and gave the company a neutral rating in a research report on Thursday, September 28th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and five have issued a buy rating to the company’s stock. Gerresheimer has an average rating of Hold and a consensus price target of €72.64 ($86.48).

Shares of Gerresheimer (ETR GXI) opened at €69.50 ($82.74) on Friday. Gerresheimer has a 12-month low of €59.97 ($71.39) and a 12-month high of €78.25 ($93.15).

TRADEMARK VIOLATION WARNING: This piece of content was first reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark law. The correct version of this piece of content can be read at https://ledgergazette.com/2017/12/12/berenberg-bank-reiterates-75-00-price-target-for-gerresheimer-gxi.html.

Gerresheimer Company Profile

Gerresheimer AG manufactures and sells specialty glass and plastic products primarily for the pharma and healthcare industry worldwide. It operates through two divisions, Plastics & Devices, and Primary Packaging Glass. The Plastics & Devices division offers drug delivery systems, such as inhalers, pen systems, and injection systems; sterile and non-sterile prefillable syringe systems for pharmaceutical and biotech industries; and disposables for various analysis systems that are used in laboratories and medical practices, quick tests for patients in medical practices or hospitals, skin-prick aids and lancets for diabetics, disposables and components for dialysis machines, and catheters and surgical devices.

Analyst Recommendations for Gerresheimer (ETR:GXI)

Receive News & Ratings for Gerresheimer AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gerresheimer AG and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply